Opinion|Videos|September 20, 2024

Future Directions in mCRPC

Panelists discuss how the treatment landscape for metastatic castration-resistant prostate cancer (mCRPC) is rapidly evolving through advancements in precision medicine and novel therapies, while emphasizing the importance of ongoing education for community oncologists to stay updated on these changes.

  • How do you see the treatment landscape for mCRPC evolving in the coming years?
  • What advice would you offer community oncologists for staying up to date with the rapidly changing field of mCRPC management?

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.


Latest CME